Skip to main content

Table 1 Summary of patient population (mITT population), (a) demographic characteristics (b) screening parameters

From: Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study

a.
Characteristic Total
N = 163
Age (yr)  
 Mean (SD) 59.5 (9.21)
Sex, n (%)  
 Male 78 (48)
Ethnicity, n (%)  
 Hispanic/Latino 1 (<1)
 Non-Hispanic/Latino 162 (>99)
Race, n (%)  
 White 145 (89)
 African American/African heritage 16 (10)
 African American/African heritage and White 1 (<1)
 American Indian or Alaskan native 1 (<1)
Height (cm)   
 Mean (SD) 170.2 (9.20)
Weight (kg)   
 Mean (SD) 79.55 (17.539)
Body mass index (kg/m2)   
 Mean (SD) 27.36 (5.115)
b.
Parameter Total N= 163
Pre-salbutamol Post-salbutamol
% predicted FEV1 (%)   
n 162 163
 Mean (SD) 47.0 (12.84) 51.1 (10.16)
FEV1/FVC (%)   
n 162 163
 Mean (SD) 51.1 (11.65) 52.3 (10.62)
FEV1 (L)   
n 162 163
 Mean (SD) 1.429 (0.5179) 1.554 (0.4727)
FVC (L)   
n 162 163
 Mean (SD) 2.803 (0.7948) 3.001 (0.8073)
Reversibility to salbutamol (%)  
n 162
 Mean (SD) 11.8 (15.31)
Reversibility to salbutamol (mL)  
n 162
 Mean (SD) 124.2 (212.56)
Mean baseline FEV1 (L)  
n 163
 Mean (SD) 1.408 (0.5282)
Mean baseline FVC (L)  
n 163
 Mean (SD) 2.763 (0.7920)
  1. Note: mean baseline was defined as the mean of the baseline values from each treatment period. If one or more values were missing, the mean baseline was the mean of the non-missing values.
  2. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; mITT, modified intent-to-treat; SD, standard deviation; UMEC, umeclidinium bromide.